[Clinical evaluation of Spersallerg preparation for non-infectious conjunctivitis and infectious conjunctivitis with a hyperergic component].
OBJECTIVE
To estimate the efficacy of "Spersallerg" eye drops from "CIBA-Vision" in conjunctivitis without any acute exogenic infection.


METHODS
The material consisted of 47 eyes, including 14 eyes with papillary conjunctivitis, 4 eyes with vermal conjunctivitis, 1 eye with giant papillary inflammation caused by wearing contact lens, 8 eyes with blepharitis and conjunctival allergic component, 6 eyes with allergy on cosmetics, 4 eyes with allergy on local anaesthetics and 10 eyes with postoperative, non-allergic conjunctival irritation. The method of evaluation was based on individual patient's opinion on his subjective symptoms and on slit-lamp examination of conjunctival, palpebral and corneal sings, typical for this type of inflammation.


CONCLUSIONS
The results showed that "Spersallerg" is clinically useful in most of allergic conjunctivitis cases, and in other inflammations with hyperergic component. It proved to be efficient as the support for causal treatment minimizing subjective and objective signs of the disease.
Nizankowska
M H
MH
Katedry i Kliniki Okulistyki AM we Wrocławiu.
Lukasik-Czerek
A
A
D000779:Anesthetics, Local / Q000009:adverse effects; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000209:etiology; D003261:Contact Lenses / Q000009:adverse effects; D003358:Cosmetics / Q000009:adverse effects; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy; D016896:Treatment Outcome
D000779:Anesthetics, Local; D003358:Cosmetics; D007093:Imidazoles; D009883:Ophthalmic Solutions; C005810:tetrahydrozoline